I/NN
kappa/NN
B/MAD-3/NN
masks/VBZ
the/DT
nuclear/JJ
localization/NN
signal/NN
of/IN
NF-kappa/NN
B/NN
p65/NN
and/CC
requires/VBZ
the/DT
transactivation/NN
domain/NN
to/TO
inhibit/VB
NF-kappa/NN
B/NN
p65/NN
DNA/NN
binding/NN
./.

The/DT
active/JJ
nuclear/JJ
form/NN
of/IN
the/DT
NF-kappa/NN
B/NN
transcription/NN
factor/NN
complex/NN
is/VBZ
composed/VBN
of/IN
two/CD
DNA/NN
binding/NN
subunits/NNS
,/,
NF-kappa/NN
B/NN
p65/NN
and/CC
NF-kappa/NN
B/NN
p50/NN
,/,
both/DT
of/IN
which/WDT
share/VBP
extensive/JJ
N-terminal/JJ
sequence/NN
homology/NN
with/IN
the/DT
v-rel/NN
oncogene/NN
product/NN
./.
=====
The/DT
NF-kappa/NN
B/NN
p65/NN
subunit/NN
provides/VBZ
the/DT
transactivation/NN
activity/NN
in/IN
this/DT
complex/JJ
and/CC
serves/VBZ
as/IN
an/DT
intracellular/JJ
receptor/NN
for/IN
a/DT
cytoplasmic/JJ
inhibitor/NN
of/IN
NF-kappa/NN
B/NN
,/,
termed/VBN
I/NN
kappa/NN
B/NN
./.
=====
In/IN
contrast/NN
,/,
NF-kappa/NN
B/NN
p50/NN
alone/RB
fails/VBZ
to/TO
stimulate/VB
kappa/NN
B-directed/JJ
transcription/NN
,/,
and/CC
based/VBN
on/IN
prior/JJ
in/FW
vitro/FW
studies/NNS
,/,
is/VBZ
not/RB
directly/RB
regulated/VBN
by/IN
I/NN
kappa/NN
B/NN
./.
=====
To/TO
investigate/VB
the/DT
molecular/JJ
basis/NN
for/IN
the/DT
critical/JJ
regulatory/JJ
interaction/NN
between/IN
NF-kappa/NN
B/NN
and/CC
I/NN
kappa/NN
B/MAD-3/NN
,/,
a/DT
series/NN
of/IN
human/JJ
NF-kappa/NN
B/NN
p65/NN
mutants/NNS
was/VBD
identified/VBN
that/WDT
functionally/RB
segregated/VBD
DNA/NN
binding/NN
,/,
I/NN
kappa/NN
B-mediated/JJ
inhibition/NN
,/,
and/CC
I/NN
kappa/NN
B-induced/JJ
nuclear/JJ
exclusion/NN
of/IN
this/DT
transcription/NN
factor/NN
./.
=====
Results/NNS
from/IN
in/FW
vivo/FW
expression/NN
studies/NNS
performed/VBN
with/IN
these/DT
NF-kappa/NN
B/NN
p65/NN
mutants/NNS
revealed/VBD
the/DT
following/NN
:/:
1/LS
)/)
I/NN
kappa/NN
B/MAD-3/NN
completely/RB
inhibits/VBZ
NF-kappa/NN
B/NN
p65-dependent/JJ
transcriptional/JJ
activation/NN
mediated/VBN
through/IN
the/DT
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
kappa/NN
B/NN
enhancer/NN
in/IN
human/JJ
T/NN
lymphocytes/NNS
,/,
2/LS
)/)
the/DT
binding/NN
of/IN
I/NN
kappa/NN
B/MAD-3/NN
to/TO
NF-kappa/NN
B/NN
p65/NN
is/VBZ
sufficient/JJ
to/TO
retarget/VB
NF-kappa/NN
B/NN
p65/NN
from/IN
the/DT
nucleus/NN
to/TO
the/DT
cytoplasm/NN
,/,
3/LS
)/)
selective/JJ
deletion/NN
of/IN
the/DT
functional/JJ
nuclear/JJ
localization/NN
signal/NN
present/JJ
in/IN
the/DT
Rel/NN
homology/NN
domain/NN
of/IN
NF-kappa/NN
B/NN
p65/NN
disrupts/VBZ
its/PRP$
ability/NN
to/TO
engage/VB
I/NN
kappa/NN
B/MAD-3/NN
,/,
and/CC
4/LS
)/)
the/DT
unique/JJ
C-terminus/NN
of/IN
NF-kappa/NN
B/NN
p65/NN
attenuates/VBZ
its/PRP$
own/JJ
nuclear/JJ
localization/NN
and/CC
contains/VBZ
sequences/NNS
that/WDT
are/VBP
required/VBN
for/IN
I/NN
kappa/NN
B-mediated/JJ
inhibition/NN
of/IN
NF-kappa/NN
B/NN
p65/NN
DNA/NN
binding/NN
activity/NN
./.
=====
Together/RB
,/,
these/DT
findings/NNS
suggest/VBP
that/IN
the/DT
nuclear/JJ
localization/NN
signal/NN
and/CC
transactivation/NN
domain/NN
of/IN
NF-kappa/NN
B/NN
p65/NN
constitute/VBP
a/DT
bipartite/JJ
system/NN
that/WDT
is/VBZ
critically/RB
involved/VBN
in/IN
the/DT
inhibitory/JJ
function/NN
of/IN
I/NN
kappa/NN
B/MAD-3/NN
./.
=====
Unexpectedly/RB
,/,
our/PRP$
in/FW
vivo/FW
studies/NNS
also/RB
demonstrate/VBP
that/IN
I/NN
kappa/NN
B/MAD-3/NN
binds/VBZ
directly/RB
to/TO
NF-kappa/NN
B/NN
p50/NN
./.
=====
This/DT
interaction/NN
is/VBZ
functional/JJ
as/IN
it/PRP
leads/VBZ
to/TO
retargeting/NN
of/IN
NF-kappa/NN
B/NN
p50/NN
from/IN
the/DT
nucleus/NN
to/TO
the/DT
cytoplasm/NN
./.
=====
However/RB
,/,
no/DT
loss/NN
of/IN
DNA/NN
binding/NN
activity/NN
is/VBZ
observed/VBN
,/,
presumably/RB
reflecting/VBG
the/DT
unique/JJ
C-terminal/JJ
domain/NN
that/WDT
is/VBZ
distinct/JJ
from/IN
that/DT
present/JJ
in/IN
NF-kappa/NN
B/NN
p65/NN
./.